Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.

ABSTRACT: Kidney transplant recipients administered belatacept-based maintenance immunosuppression present with a more favorable metabolic profile, reduced incidence of de novo donor-specific antibodies (DSAs), and improved renal function and long-term patient/graft survival relative to individuals receiving calcineurin inhibitor (CNI)-based immunosuppression. However, the rates and severity of acute rejection (AR) are greater with the approved belatacept-based regimen than with CNI-based immunosuppression. Although these early co-stimulation blockade-resistant rejections are typically steroid sensitive, the higher rate of cellular AR has led many transplant centers to adopt immunosuppressive regimens that differ from the approved label. This article summarizes the available data on these alternativ

SUBMITTER: Kirk AD 

PROVIDER: S-EPMC8246831 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature